explain the market cap, page-39

First 39 Last

Share
Profile

Follow
jaykay

307 Posts.

27

11/06/20

09:18

Post #: 45151746
Share

Originally posted by imback: ↑

Cheers. I was just wanted to understand if I had a third independent clinician voice on the results (besides the two in the conference call). Your conclusions/insights are remarkably similar to theirs insofar as what you have expressed to date.

So, a good sign for me given I am not an ophthalmologist dealing with injecting patients for wAMD and DME, if ppl didn't work that out yet

So my next question is whether there is a need to do a phase 2b with a higher statistical power and just focused on patients who have reached their improvement limit on Eylea or similar drugs. The clinicians were very keen to have an alternative to steroids. They were estimating this population size was around 50-60% of all patients. The alternative mentioned by MB was to do a phase 3 starting with treatment naive patients and then have various check points where they would take out non-responders to eventually find the most likely group to benefit. This was a more standard form for FDA trials, she explained.

Expand

Absolutely. All OPT have to do is increase the sample size and these results will reach statistical significance.

Let's not forget how well OPT did to show these results to the market just before COVID caused a major disruption to clinic visits.

Seriously. Results like the ones they reported yesterday don't happen by accident, or as a statistical anomaly. If they give another 100 patients a monthly injection for 3 months, I reckon that's all that would be required to achieve statistical significance.

If you have a look at the clinical trial on clinicaltrials.org, it looks like the study is set to be finalised in August 2020.

PS: if you're not an ophthalmologist, you're doing well. You have a solid understanding of this trial

OPT Price at posting: $3.05 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply